SCHEMBL403556

SCHEMBL403556

CC(C)(C)OC(=O)N1CCc2[nH]c3nccc(Cl)c3c2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 2/20 0.44
MKNK1 Q9BUB5 4/20 0.43
ESR2 Q92731 1/20 0.43
POLB P06746 1/20 0.41
CGAS Q8N884 1/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
NR1H2 P55055 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
F12 P00748 1/20 0.40
PARP1 P09874 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
BAZ2B Q9UIF8 2/20 0.39
LMNA P02545 1/20 0.39
PABPC1 P11940 1/20 0.39
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CCNT1 O60563 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2484902 0.88 MKNK1 (0.46) CDK9MKNK1ESR2POLBMAPT
SCHEMBL2485934 0.88 MKNK1 (0.46) CDK9MKNK1ESR2POLBMAPT
SCHEMBL17081928 0.80 MKNK1 (0.39) CDK9MKNK1ESR2MAPTDDB1
SCHEMBL4790168 0.80 CFTR (0.46) MKNK1ESR2CGASMAPK1NR1H2
SCHEMBL404753 0.79 BAZ2B (0.48) CDK9MKNK1ESR2CGASMAPT
SCHEMBL14872980 0.78 ESR2 (0.49) MKNK1ESR2POLBMAPTMAPK1
SCHEMBL31240800 0.77 CDK9 (0.45) CDK9NR1H2F12CCNT1
SCHEMBL31240765 0.77 CDK9 (0.45) CDK9NR1H2F12CCNT1
SCHEMBL27053264 0.75 LMNA (0.44) MKNK1ESR2CGASMAPTMAPK1
SCHEMBL30552452 0.75 LMNA (0.44) MKNK1ESR2CGASMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 EP disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 WO disclosed
EP-2367822-B1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2016-10-05 EP disclosed
US-8853391-B2 Tricyclic azaindoles MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-20120022060-A1 Tricyclic Azaindoles MERCK PATENT GMBH (DE) 2012-01-26 US disclosed
EP-2367822-A1 TRICYCLIC AZAINDOLES Merck Patent GmbH (DE) 2011-09-28 EP disclosed
WO-2010080253-A1 TRICYCLIC AZAINDOLES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022060-A1 Tricyclic Azaindoles AZI2, DCK, PPP2CA CDK9 32/4885MKNK1 54/4885ESR2 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.